Clinical Scorecard: Utilization of Exclusive Enteral Nutrition in Children with Crohn's Disease: Insights from a Secondary Analysis of the CLARA Registry Study
At a Glance
Category
Detail
Condition
Key Mechanisms
Exclusive enteral nutrition (EEN) is recommended as first-line therapy.
Target Population
Care Setting
Key Highlights
EEN is underutilized despite being recommended as first-line therapy for active luminal Crohn's disease.
Registry documentation showed a non-significant increase in enteral nutrition use.
Adherence to guideline-recommended EEN duration was low in both intervention and control groups.
Steroid use was higher in the control group compared to the intervention group.
Guideline-Based Recommendations
Diagnosis
Management
Exclusive enteral nutrition (EEN) should be utilized as first-line therapy.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Children diagnosed with Crohn's disease, analyzed from the CLARA registry.
Combination therapies included immunosuppressants, 5-ASA, biologicals, and/or steroids.
